ATG-019

ATG-019 · Antengene Therapeutics Limited

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ATG-019, covering 2024-04-30 to 2024-04-30. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma [Phase 1]

See pricing